Short-term intraocular pressure changes following intravitreal injections of aflibercept 8mg versus 2mg: A prospective comparative study
European Journal of Ophthalmology · 27.07.2026
DOI: 10.1177/11206721261471322 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Ophthalmology, online erschienen am 27.07.2026. Verfasst von Imran Karim Janmohamed und 7 weiteren Autor:innen. Beteiligte Einrichtung: Ophthalmology Department, Maidstone Hospital, Maidstone, UK. Die Arbeit nennt 41 Literaturangaben.
Abstract (Originalsprache)
Purpose
The increased injection volume of aflibercept 8 mg (0.07 ml versus 0.05 ml) raises theoretical concerns regarding intraocular pressure (IOP) effects. This study evaluated acute IOP dynamics following aflibercept 8 mg compared to aflibercept 2 mg and identified predictive factors for pressure elevation.
Methods
140 eyes of 127 patients receiving aflibercept 8 mg (70 eyes) or 2 mg (70 eyes) between January-December 2025 were included. IOP was measured at baseline (T0), immediately post-injection (T1), and 30 min post-injection (T2). Linear mixed-effects models assessed the effects of time, treatment group, and time-by-treatment interactions. Multivariable mixed-effects logistic regression was used to identify predictors of IOP >21mmHg and IOP elevation >5mmHg at T2.
Results
Both formulations produced significant IOP elevations from baseline at T1 and T2 ( p < 0.001 within each group). Mean IOP increased from 14.0 mmHg to 39.3 mmHg (aflibercept 2 mg) and 14.5 mmHg to 39.3 mmHg (aflibercept 8 mg) immediately post-injection, with near-complete resolution by 30 min (16.9 vs 17.7 mmHg). No significant between-group differences were identified at any timepoint. Pre-existing glaucoma/OHT was the only consistent independent predictor of both IOP >21 mmHg (OR 3.00–3.31, p = 0.024–0.038) and IOP elevation >5 mmHg from baseline (OR 10.45–11.75, p < 0.001) at T2; aflibercept formulation was not associated with either outcome. No injection required paracentesis.
Conclusion
Aflibercept 8 mg demonstrates comparable IOP dynamics to aflibercept 2 mg. Glaucoma/OHT represents the strongest predictor of early pressure elevation, warranting enhanced monitoring.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ophthalmology Department, Maidstone Hospital, Maidstone, UK.
- GKT School of Medical Education, King's College London, London, UK.
- Ophthalmology Department, Frimley Park Hospital, Camberley, UK.
- Hammersmith Hospital, London, UK.
ORCID-Profile: Imran Karim Janmohamed, Haasher Monib, Anibe Ata
Zitieren
APA
Janmohamed, I. K., Sahbi, S., Mahmood, A., Monib, H., Nawaz, H., Hannan, S., Ata, A., & Membrey, L. (2026). Short-term intraocular pressure changes following intravitreal injections of aflibercept 8mg versus 2mg: A prospective comparative study. European Journal of Ophthalmology. https://doi.org/10.1177/11206721261471322
Vancouver
Janmohamed IK, Sahbi S, Mahmood A, Monib H, Nawaz H, Hannan S, et al. Short-term intraocular pressure changes following intravitreal injections of aflibercept 8mg versus 2mg: A prospective comparative study. European Journal of Ophthalmology. 2026. doi:10.1177/11206721261471322
BibTeX
@article{Janmohamed2026,
author = {Janmohamed, Imran Karim and Sahbi, Saleh and Mahmood, Arsam and Monib, Haasher and Nawaz, Hamza and Hannan, Shabeeba and Ata, Anibe and Membrey, Luke},
title = {Short-term intraocular pressure changes following intravitreal injections of aflibercept 8mg versus 2mg: A prospective comparative study},
journal = {European Journal of Ophthalmology},
year = {2026},
doi = {10.1177/11206721261471322}
}
EUVIMED